Table 1.
Baseline demographic, medical, and behavioral profile of HIITTS trial participants, overall and by group assignment
| Overall (n = 63) | Usual Care (n = 28) | HIIT (n = 35) | ||||
|---|---|---|---|---|---|---|
| No. of patients | % | No. of patients | % | No. of patients | % | |
| Demographic Profile | ||||||
| Age, years | ||||||
| Mean (SD) | 43.7 (10.8) | 43.3 (9.9) | 44.0 (11.6) | |||
| Range | 21–61 | 22–61 | 21–60 | |||
| Caucasian | 57 | 90.5 | 27 | 96.4 | 30 | 85.7 |
| Completed university | 42 | 66.7 | 19 | 67.9 | 23 | 65.7 |
| Married | 43 | 68.3 | 18 | 64.3 | 25 | 71.4 |
| Medical Profile | ||||||
| Time since diagnosis, years | ||||||
| Mean (SD) | 8.0 (5.5) | 7.5 (5.5) | 8.5 (5.5) | |||
| Range | 1–20 | 1–20 | 1–20 | |||
| Treatment years | ||||||
| ≤2000 | 8 | 12.7 | 4 | 14.3 | 4 | 11.4 |
| 2001–2005 | 16 | 25.4 | 6 | 21.4 | 10 | 28.6 |
| 2006–2010 | 17 | 27.0 | 8 | 28.6 | 9 | 25.7 |
| ≥2011 | 22 | 34.9 | 10 | 35.7 | 12 | 34.3 |
| Disease stage at diagnosis | ||||||
| Localised | 41 | 65.1 | 20 | 71.4 | 22 | 62.9 |
| Advanced | 22 | 34.9 | 8 | 28.6 | 13 | 37.1 |
| Surgical protocol | ||||||
| Single orchidectomy | 58 | 92.1 | 27 | 96.4 | 31 | 88.6 |
| Received radiotherapy | 11 | 17.5 | 5 | 17.9 | 6 | 17.1 |
| Abdominal radiotherapy exposure | 10 | 15.9 | 4 | 14.3 | 6 | 17.1 |
| Received chemotherapy | 23 | 36.5 | 8 | 28.6 | 15 | 42.9 |
| 2 cycles of Cisplatin-based therapy | 1 | 1.6 | 1 | 3.6 | 0 | 0.0 |
| 3 cycles of Cisplatin-based therapy | 16 | 25.4 | 7 | 25.0 | 9 | 25.7 |
| 4 cycles of Cisplatin-based therapy | 5 | 7.9 | 1 | 3.6 | 4 | 11.4 |
| 6 cycles of Cisplatin-based therapy | 1 | 1.6 | 0 | 0.0 | 1 | 2.9 |
| Physical/Behavioral Profile | ||||||
| VO2peak (ml O2/kg/min) | ||||||
| Mean (SD) | 37.0 (6.2) | 37.0 (7.2) | 37.1 (5.7) | |||
| Low (<35th percentile) | 35 | 55.6 | 17 | 60.7 | 18 | 51.4 |
| Average (≥35th & ≤65th percentile) | 19 | 30.2 | 5 | 17.9 | 14 | 40.0 |
| High (>65th percentile) | 9 | 14.3 | 6 | 21.4 | 3 | 8.6 |
| Testosterone (nmol/L) | ||||||
| Mean (SD) | 14.9 (5.5) | 14.6 (4.8) | 15.1 (6.1) | |||
| Low (<14.5 nmol/L) | 31 | 49.2 | 12 | 42.9 | 19 | 54.3 |
| High (≥14.5 nmol/L) | 32 | 50.8 | 16 | 57.1 | 16 | 45.7 |
| Fatigue | ||||||
| Mean (SD) | 41.4 (8.5) | 42.8 (8.4) | 40.0 (8.7) | |||
| Fatigued [≤42 (FACT-F)] | 28 | 44.4 | 9 | 32.1 | 19 | 54.3 |
| Not Fatigued [>42 (FACT-F)] | 35 | 55.6 | 19 | 67.9 | 16 | 45.7 |
| Aerobic exercise (min/week) | ||||||
| Mean (SD) | 52 (52) | 40 (44) | 62 (57) | |||
| Not meeting AET guidelines | 40 | 63.5 | 21 | 75.0 | 19 | 54.3 |
| Meeting AET guidelines | 23 | 36.5 | 7 | 25.0 | 16 | 45.7 |
HIIT high-intensity interval training, No. number, SD standard deviation, VO2peak peak aerobic exercise capacity, ml milliliter, O2 oxygen, kg kilograms, BMI body mass index, min minute, nmol/L nanomole per litre, FACT-F functional assessment of cancer therapy fatigue scale, AET aerobic exercise training